NCT05456646

Brief Summary

This study aims to evaluate the relationship between sarcopenia and functional outcomes with temporal muscle mass change.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 11, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 13, 2022

Completed
2 days until next milestone

Study Start

First participant enrolled

July 15, 2022

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

September 5, 2023

Status Verified

January 1, 2023

Enrollment Period

1.6 years

First QC Date

July 11, 2022

Last Update Submit

September 1, 2023

Conditions

Outcome Measures

Primary Outcomes (14)

  • Functional Ambulation Scale

    This scale consists of six levels of function, ranging from 0 ( non-ambulatory ) to 5 (independently ambulatory).

    Baseline

  • Functional Ambulation Scale

    This scale consists of six levels of function, ranging from 0 ( non-ambulatory ) to 5 (independently ambulatory).

    6. month

  • The Functional Independence Measure (FIM)

    FIM is a scale that assesses 18 activities, including self-care, sphincter control, transfer, movement, communication, and social awareness. Total scores range from 18 to 126 (dependent in all domains - independent in all domains).

    Baseline

  • The Functional Independence Measure (FIM)

    FIM is a scale that assesses 18 activities, including self-care, sphincter control, transfer, movement, communication, and social awareness. Total scores range from 18 to 126 (dependent in all domains - independent in all domains).

    6.month

  • Modified Rankin Scale (mRS)

    It categorizes poststroke disability into six levels ranging from 0 to 5, with absence of symptoms rated as 0 and severe disability or bedriddenness rated as 5. An mRS score of 2 or less was defined as a good outcome, and an mRS score above 2 was defined as a poor outcome.

    Baseline

  • Modified Rankin Scale (mRS)

    It categorizes poststroke disability into six levels ranging from 0 to 5, with absence of symptoms rated as 0 and severe disability or bedriddenness rated as 5. An mRS score of 2 or less was defined as a good outcome, and an mRS score above 2 was defined as a poor outcome.

    6. month

  • Handgrip strength

    With the JAMAR Hand Dynamometer, 3 measurements will be taken for both hands 60 seconds apart in the standard position and the highest reading will be recorded.

    Baseline

  • Handgrip strength

    With the JAMAR Hand Dynamometer, 3 measurements will be taken for both hands 60 seconds apart in the standard position and the highest reading will be recorded.

    6. month

  • Dual energy X-ray absorptiometry (DEXA)

    DEXA can be used to determine lean body mass and total body fat. The appendicular skeletal mass index will be used in the evaluation of sarcopenia and in other analyzes.

    Baseline

  • Dual energy X-ray absorptiometry (DEXA)

    DEXA can be used to determine lean body mass and total body fat. The appendicular skeletal mass index will be used in the evaluation of sarcopenia and in other analyzes.

    6.month

  • Bioelectrical impedance analysis (BIA)

    Body water mass, total body fat, and muscle mass can be determined with BIA.The appendicular skeletal mass index will be used in the evaluation of sarcopenia and in other analyzes.

    Baseline

  • Bioelectrical impedance analysis (BIA)

    Body water mass, total body fat, and muscle mass can be determined with BIA.The appendicular skeletal mass index will be used in the evaluation of sarcopenia and in other analyzes.

    6.month

  • Functional Oral Intake Scale

    The scale is rated with values between 1 and 7. Level 1-3 refers to tube-dependent feeding, level 4-6 to full oral feeding with restrictions, and level 7 to oral feeding without restrictions.

    Baseline

  • Functional Oral Intake Scale

    The scale is rated with values between 1 and 7. Level 1-3 refers to tube-dependent feeding, level 4-6 to full oral feeding with restrictions, and level 7 to oral feeding without restrictions.

    6. month

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A tertiary health care facility

You may qualify if:

  • Diagnosis of stroke
  • Presence of cranial MRI/CT in hospital records

You may not qualify if:

  • Medically unstable condition (presence or high risk of impaired consciousness, respiration, or circulation).
  • Severe cognitive impairment
  • Patients who require intensive care unit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Izmir Bozyaka Research and Training Hostpital

Izmir, Turkey (Türkiye)

Location

Related Publications (3)

  • Ryan AS, Ivey FM, Serra MC, Hartstein J, Hafer-Macko CE. Sarcopenia and Physical Function in Middle-Aged and Older Stroke Survivors. Arch Phys Med Rehabil. 2017 Mar;98(3):495-499. doi: 10.1016/j.apmr.2016.07.015. Epub 2016 Aug 13.

    PMID: 27530769BACKGROUND
  • Nozoe M, Kanai M, Kubo H, Yamamoto M, Shimada S, Mase K. Prestroke sarcopenia and functional outcomes in elderly patients who have had an acute stroke: A prospective cohort study. Nutrition. 2019 Oct;66:44-47. doi: 10.1016/j.nut.2019.04.011. Epub 2019 Apr 25.

    PMID: 31207438BACKGROUND
  • Nakanishi N, Okura K, Okamura M, Nawata K, Shinohara A, Tanaka K, Katayama S. Measuring and Monitoring Skeletal Muscle Mass after Stroke: A Review of Current Methods and Clinical Applications. J Stroke Cerebrovasc Dis. 2021 Jun;30(6):105736. doi: 10.1016/j.jstrokecerebrovasdis.2021.105736. Epub 2021 Mar 20.

    PMID: 33756264BACKGROUND

MeSH Terms

Conditions

StrokeSarcopenia

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesMuscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Officials

  • Bugra Ince, MD

    Izmir Bozyaka Education and Resarch Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 11, 2022

First Posted

July 13, 2022

Study Start

July 15, 2022

Primary Completion

March 1, 2024

Study Completion

April 1, 2024

Last Updated

September 5, 2023

Record last verified: 2023-01

Locations